Phase 1 clinical trial of Trametes versicolor in women with breast cancer
Torkelson CJ, Sweet E, Martzen MR
Published in ISRN Oncology
Methodology
Dose-escalation phase I trial of oral Trametes versicolor for 6 weeks in women after radiotherapy for breast cancer
Key Findings
Trametes versicolor was well tolerated up to 9 g/day and was associated with dose-dependent recovery of lymphocyte and natural killer cell counts
Conclusions
Trametes versicolor is safe and may support immune reconstitution after breast cancer radiotherapy
Limitations
Phase I dose-finding, very small sample, no efficacy endpoints
Supplements Studied
Trametes versicolor was well tolerated up to 9 g/day with dose-dependent recovery of lymphocyte and natural killer cell counts
Outcomes Measured
Lymphocyte and natural killer cell counts recovered in a dose-dependent manner with Trametes versicolor
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.